Drugs / pexelizumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00088179 | Jul 2004 → Oct 2005 | coronary artery disorder | Alexion Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 3 | NCT00091637 | Apr 2004 → May 2007 | acute myocardial infarction | Procter and Gamble | Completed | Missed primary |
| Phase 3 | NCT00048308 | Jan 2002 → Mar 2003 | coronary artery disorder | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pexelizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00048308 ↗ |
| Known as | 5G1.1-SC | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107979 ↗ |
| Known as | H-5G1.1 SCFV | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107979 ↗ |
| Known as | H5G1.1 SCFV (CDR) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107979 ↗ |
| Action | Inhibit | “blocks complement release” NCT00048308 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2107979 ↗ |
| Route | Intravenous | “The patients were randomly assigned to receive intravenous pexelizumab or placebo.” PMID 20880552 ↗ Sep 2010 |
| Target | C5 | “Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting” PMID 20880552 ↗ Sep 2010 |